Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

被引:61
|
作者
Poortvliet, Rosalinde K. E. [1 ]
Ford, Ian [2 ]
Lloyd, Suzanne M. [2 ]
Sattar, Naveed [3 ]
Mooijaart, Simon P. [4 ,5 ]
de Craen, Anton J. M. [4 ]
Westendorp, Rudi G. J. [4 ,6 ]
Jukema, J. Wouter [7 ]
Packard, Christopher J. [8 ]
Gussekloo, Jacobijn [1 ]
de Ruijter, Wouter [1 ]
Stott, David J. [8 ]
机构
[1] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Univ Glasgow, Dept Vasc Biochem, Glasgow, Lanark, Scotland
[4] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands
[5] Inst Evidence Based Med Old Age, Leiden, Netherlands
[6] Netherlands Consortium Healthy Ageing, Leiden, Netherlands
[7] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
[8] Univ Glasgow, Glasgow Royal Infirm, Fac Med, Acad Sect Geriatr Med, Glasgow G31 2ER, Lanark, Scotland
来源
PLOS ONE | 2012年 / 7卷 / 12期
基金
英国惠康基金;
关键词
SOCIETY-OF-HYPERTENSION; PROGNOSTIC-SIGNIFICANCE; GUIDELINES; INFARCTION; PREDICTOR; MORTALITY; STROKE;
D O I
10.1371/journal.pone.0052438
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Variability in blood pressure predicts cardiovascular disease in young-and middle-aged subjects, but relevant data for older individuals are sparse. We analysed data from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study of 5804 participants aged 70-82 years with a history of, or risk factors for cardiovascular disease. Visit-to-visit variability in blood pressure (standard deviation) was determined using a minimum of five measurements over 1 year; an inception cohort of 4819 subjects had subsequent in-trial 3 years follow-up; longer-term follow-up (mean 7.1 years) was available for 1808 subjects. Higher systolic blood pressure variability independently predicted long-term follow-up vascular and total mortality (hazard ratio per 5 mmHg increase in standard deviation of systolic blood pressure = 1.2, 95% confidence interval 1.1-1.4; hazard ratio 1.1, 95% confidence interval 1.1-1.2, respectively). Variability in diastolic blood pressure associated with increased risk for coronary events (hazard ratio 1.5, 95% confidence interval 1.2-1.8 for each 5 mmHg increase), heart failure hospitalisation (hazard ratio 1.4, 95% confidence interval 1.1-1.8) and vascular (hazard ratio 1.4, 95% confidence interval 1.1-1.7) and total mortality (hazard ratio 1.3, 95% confidence interval 1.1-1.5), all in long-term follow-up. Pulse pressure variability was associated with increased stroke risk (hazard ratio 1.2, 95% confidence interval 1.0-1.4 for each 5 mmHg increase), vascular mortality (hazard ratio 1.2, 95% confidence interval 1.0-1.3) and total mortality (hazard ratio 1.1, 95% confidence interval 1.0-1.2), all in long-term follow-up. All associations were independent of respective mean blood pressure levels, age, gender, in-trial treatment group (pravastatin or placebo) and prior vascular disease and cardiovascular disease risk factors. Our observations suggest variability in diastolic blood pressure is more strongly associated with vascular or total mortality than is systolic pressure variability in older high-risk subjects.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Lloyd, Suzanne M.
    Stott, David J.
    de Craen, Anton J. M.
    Kearney, Patricia M.
    Sattar, Naveed
    Perry, Ivan
    Packard, Christopher J.
    Briggs, Andrew
    Marchbank, Laura
    Comber, Harry
    Jukema, J. Wouter
    Westendorp, Rudi G. J.
    Trompet, Stella
    Buckley, Brendan M.
    Ford, Ian
    [J]. PLOS ONE, 2013, 8 (09):
  • [22] Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    Shepherd, J
    Blauw, GJ
    Murphy, MB
    Bollen, ELEM
    Buckley, BM
    Cobbe, SM
    Ford, I
    Gaw, A
    Hyland, M
    Jukema, JW
    Kamper, AM
    Macfarlane, PW
    Meinders, AE
    Norrie, J
    Packard, CJ
    Perry, IJ
    Stott, DJ
    Sweeney, BJ
    Twomey, C
    Westendorp, RGJ
    [J]. LANCET, 2002, 360 (9346): : 1623 - 1630
  • [23] Markers of cholesterol absorption and synthesis in individuals without and with CHD events during treatment with pravastatin: Insights from the prospective study of pravastatin in the elderly at risk (PROSPER) trial
    Matthan, Nirupa R.
    Resteghini, Nancy
    Lichtenstein, Alice H.
    Robertson, Michele
    Shepherd, James
    Schaefer, Ernst J.
    [J]. CIRCULATION, 2007, 116 (16) : 818 - 819
  • [24] Blood pressure variability: cardiovascular risk integrator or independent risk factor?
    Blacher, J.
    Safar, M. E.
    Ly, C.
    de Edelenyi, F. Szabo
    Hercberg, S.
    Galan, P.
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2015, 29 (02) : 122 - 126
  • [25] Blood pressure variability: cardiovascular risk integrator or independent risk factor?
    J Blacher
    M E Safar
    C Ly
    F Szabo de Edelenyi
    S Hercberg
    P Galan
    [J]. Journal of Human Hypertension, 2015, 29 : 122 - 126
  • [26] Blood Pressure Variability, Cardiovascular Risk, and Risk for Renal Disease Progression
    Parati, Gianfranco
    Ochoa, Juan E.
    Bilo, Grzegorz
    [J]. CURRENT HYPERTENSION REPORTS, 2012, 14 (05) : 421 - 431
  • [27] Blood Pressure Variability, Cardiovascular Risk, and Risk for Renal Disease Progression
    Gianfranco Parati
    Juan E. Ochoa
    Grzegorz Bilo
    [J]. Current Hypertension Reports, 2012, 14 : 421 - 431
  • [28] In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study
    Postmus, Iris
    Johnson, Paul C. D.
    Trompet, Stella
    de Craen, Anton J. M.
    Slagboom, P. Eline
    Devlin, James J.
    Shiffman, Dov
    Sacks, Frank M.
    Kearney, Patricia M.
    Stott, David J.
    Buckley, Brendan M.
    Sattar, Naveed
    Ford, Ian
    Westendorp, Rudi G. J.
    Jukema, J. Wouter
    [J]. ATHEROSCLEROSIS, 2014, 235 (01) : 58 - 64
  • [29] Homocysteine Levels and Treatment Effect in the Prospective Study of Pravastatin in the Elderly at Risk
    Drewes, Yvonne M.
    Poortvliet, Rosalinde K. E.
    Blom, Jeanet W.
    de Ruijter, Wouter
    Westendorp, Rudi G. J.
    Stott, David J.
    Blom, Henk J.
    Ford, Ian
    Sattar, Naveed
    Jukema, J. Wouter
    Assendelft, Willem J. J.
    de Craen, Anton J. M.
    Gussekloo, Jacobijn
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2014, 62 (02) : 213 - 221
  • [30] C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER)
    Sattar, Naveed
    Murray, Heather M.
    McConnachie, Alex
    Blauw, Gerard J.
    Bollen, Edward L. E. M.
    Buckley, Brendan M.
    Cobbe, Stuart M.
    Ford, Ian
    Gaw, Allan
    Hyland, Michael
    Jukema, J. Wouter
    Kamper, Adriaan M.
    Macfarlane, Peter W.
    Murphy, Michael B.
    Packard, Chris J.
    Perry, Ivan J.
    Stott, David J.
    Sweeney, Brian J.
    Twomey, Cillian
    Westendorp, Rudi G. J.
    Shepherd, James
    [J]. CIRCULATION, 2007, 115 (08) : 981 - 989